AMCP Nexus 2021: What’s Promising, What’s Problematic About Prescription Digital Therapeutics
October 21st 2021A panel discussion on prescription digital therapeutics identified them as a sweet spot for value-based agreements and collection of real-world evidence. But should they be paid for through the pharmacy benefit? And is there enough evidence available for payers and PBMs to make sound coverage and formulary decisions? For answers, stay tuned.
Read More
AMCP Nexus 2021: How SCAN Turned Healthcare Disparity Talk Into Action
October 20th 2021The Southern California Medicare Advantage health plan zeroed in on medication adherence among its Black and Latinx members and took a multifaceted approach, which included cultural humility training and pairing staff and members had language and a cultural background in common.
Read More
Loucks, manager of specialty clinical pharmacy programs and formulary at Kaiser Permanente Washington, discusses metrics that might give healthcare providers an incentive to address healthcare disparities and concrete steps that could be taken to turn the talk about addressing healthcare disparities into a reality.
Read More
AMCP Nexus 2021: What the Future May Hold for Mavacamten
October 19th 2021If the new drug is approved, a Mayo Clinic expert on hypertrophic cardiomyopathy sees the new medication as probably being among the second-line choices for patients who don’t respond to beta blockers and calcium channel blockers.
Read More